Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada.
| Revenue (Most Recent Fiscal Year) | $16.10M |
| Net Income (Most Recent Fiscal Year) | $-42.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.14 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.91 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -262.88% |
| Net Margin (Trailing 12 Months) | -264.45% |
| Return on Equity (Trailing 12 Months) | -90.28% |
| Return on Assets (Trailing 12 Months) | -73.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.07 |
| Inventory Turnover (Trailing 12 Months) | 0.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.83 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.27 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.41 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.41 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 36.34M |
| Free Float | 35.79M |
| Market Capitalization | $259.81M |
| Average Volume (Last 20 Days) | 0.19M |
| Beta (Past 60 Months) | 0.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.52% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |